Clinical Trial Update: Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial of a neoantigen-specific adoptive T cell therapy for newly diagnosed MGMT-negative glioblastoma multiforme, sponsored by TVAX Biomedi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Neoantigen-specific Adoptive T Cell Therapy

Snippet

Sponsor: TVAX Biomedical | Conditions: Glioblastoma Multiforme of Brain | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING